October 31, 2007Open Access

Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine

SSShinichi SakuramotoSaitama International Medical Center MSMitsuru SasakoYodogawa Christian Hospital TYToshiharu YamaguchiThe Cancer Institute Hospital

Key Points

Key points are not available for this paper at this time.

Abstract

S-1 is an effective adjuvant treatment for East Asian patients who have undergone a D2 dissection for locally advanced gastric cancer. (ClinicalTrials.gov number, NCT00152217 ClinicalTrials.gov.).

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Sakuramoto et al. (Wed,) studied this question.

synapsesocial.com/papers/69d750edb54ccf0cfef30db1 https://doi.org/https://doi.org/10.1056/nejmoa072252

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators1996 · 824 citations
2Discrete sequential boundaries for clinical trials1983 · 1,746 citations
3Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.1993 · 552 citations
4Clinical implications of dihydropyrimidine dehydrogenase inhibition.1999 · 68 citations
5Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients1993 · 108 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper